A randomised, double-blind, four-way, crossover trial comparing the 24-h FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with chronic obstructive pulmonary disease

Respiratory Medicine
G F JoosRené Aalbers

Abstract

This randomised, double-blind, four-way, crossover, Phase II study compared the 24-h forced expiratory volume in 1 s (FEV1) profile of alternative dosing frequencies of two total daily doses of olodaterol (5 and 10 μg) in patients with chronic obstructive pulmonary disease (COPD). Patients received olodaterol 2 μg twice daily (BID), 5 μg BID, 5 μg once daily (QD) and 10 μg QD in a randomised sequence over 3-week treatment periods. Co-primary end points were FEV1 area under the curve from 0 to 12 h (AUC0-12) and area under the curve from 12 to 24 h (AUC12-24) responses. Additional lung-function responses, pharmacokinetics and safety were assessed. 47 patients were treated. All olodaterol doses provided significant increases in FEV1 versus baseline (p < 0.001) and FEV1 time profiles were nearly identical for olodaterol 5 and 10 μg QD. Olodaterol 5 μg QD demonstrated improved FEV1 AUC0-12 and similar AUC12-24 versus 2 μg BID. Olodaterol 5 μg QD showed slightly increased FEV1 AUC0-12 but lower AUC12-24 compared to 5 μg BID. Bronchodilation over 24 h was similar for olodaterol 5 μg QD and BID. All doses were well tolerated. Olodaterol 5 μg QD is efficacious in COPD, with a superior bronchodilatory profile compared to 2 μg BID, which...Continue Reading

References

Jun 29, 2004·The European Respiratory Journal·B R CelliUNKNOWN ATS/ERS Task Force
Feb 5, 2005·Respirology : Official Journal of the Asian Pacific Society of Respirology·UNKNOWN Asia Pacific COPD Roundtable Group
Jul 19, 2005·Expert Opinion on Investigational Drugs·Mario CazzolaJan Lötvall
Aug 2, 2005·The European Respiratory Journal·M R MillerUNKNOWN ATS/ERS Task Force
Jul 30, 2009·Current Opinion in Allergy and Clinical Immunology·Stefano Guerra
Dec 17, 2009·The Journal of Allergy and Clinical Immunology·Paul M O'ByrneLouis-Philippe Boulet
Aug 16, 2011·Pulmonary Pharmacology & Therapeutics·J A van NoordP J G Cornelissen
Mar 24, 2012·The European Respiratory Journal·Paul W JonesEsther Garcia Gil
Jun 27, 2014·International Journal of Chronic Obstructive Pulmonary Disease·Gary T FergusonPaul Sachs

❮ Previous
Next ❯

Citations

Mar 17, 2004·International Journal of Pharmaceutics·Masayo HigashiyamaKakuji Tojo
Oct 13, 2018·Expert Opinion on Pharmacotherapy·Andrea S Melani

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.